Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for
hematologic malignancies, but patients can develop long-term adverse events, including …

The number of patients surviving≥ 5 years after initial cancer diagnosis has significantly
increased during the last decades due to considerable improvements in the treatment of …

Background Rituximab added to chemotherapy prolongs survival among adults with B-cell
cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non …

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …

Importance To date, the risk of developing second primary cancers (SPCs) after the first
primary melanoma has not been studied in the era of immune checkpoint inhibitors (ICIs) …

Background While radiotherapy is a major risk factor for thyroid cancer after childhood
cancer, factors contributing to increased thyroid cancer risk after adulthood cancer remain …

We determined first-and second-line regimens, including hematopoietic stem cell
transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged≥ 20 yr (n …

Considering treatment changes and an improved prognosis of non-Hodgkin lymphoma
(NHL) over time, knowledge regarding long-term health outcomes, including late effects of …

Purpose The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well
described, and rates of second primary malignancies (SPM) in these patients are not known …

Previous studies have demonstrated that programmed death-1 ligand 1 (PD-L1) expressed
in an aggressive activated B-cell (ABC)/non-germinal center B cell–like (GCB) subtype of …